Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,197
archived clinical trials in
Atrial Fibrillation

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated:  3/4/2013
University of Cincinnati
726
mi
from
Cincinnati, OH
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated: 3/4/2013
University of Cincinnati
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated:  3/4/2013
Riverside Methodist Hospital
810
mi
from
Columbus, OH
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated: 3/4/2013
Riverside Methodist Hospital
810
mi
from
Columbus, OH
Click here to add this to my saved trials
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated:  3/4/2013
Genesis Healthcare Systems
mi
from
Zanesville, OH
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated: 3/4/2013
Genesis Healthcare Systems
mi
from
Zanesville, OH
Click here to add this to my saved trials
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated:  3/4/2013
Doylestown Hospital
1227
mi
from
Doylestown, PA
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated: 3/4/2013
Doylestown Hospital
1227
mi
from
Doylestown, PA
Click here to add this to my saved trials
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated:  3/4/2013
Albert Einstein Medical Center
1225
mi
from
Philadelphia, PA
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated: 3/4/2013
Albert Einstein Medical Center
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated:  3/4/2013
Centennial Medical Center
601
mi
from
Ashland City, TN
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated: 3/4/2013
Centennial Medical Center
601
mi
from
Ashland City, TN
Click here to add this to my saved trials
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated:  3/4/2013
Plaza Medical Center
347
mi
from
Fort Worth, TX
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated: 3/4/2013
Plaza Medical Center
347
mi
from
Fort Worth, TX
Click here to add this to my saved trials
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated:  3/4/2013
Baylor All Saints Medical Center
348
mi
from
Fort Worth, TX
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated: 3/4/2013
Baylor All Saints Medical Center
348
mi
from
Fort Worth, TX
Click here to add this to my saved trials
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated:  3/4/2013
Bellin Memorial Hospital
689
mi
from
Green Bay, WI
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population
Status: Enrolling
Updated: 3/4/2013
Bellin Memorial Hospital
689
mi
from
Green Bay, WI
Click here to add this to my saved trials
Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation
Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation In Patients Undergoing Successful Electrical Cardioversion to Sinus Rhythm
Status: Enrolling
Updated:  3/28/2013
Creighton University Medical Center
262
mi
from
Omaha, NE
Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation
Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation In Patients Undergoing Successful Electrical Cardioversion to Sinus Rhythm
Status: Enrolling
Updated: 3/28/2013
Creighton University Medical Center
262
mi
from
Omaha, NE
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
AZ Heart Rhythm Center
mi
from
Phoenix, AZ
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
AZ Heart Rhythm Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Clinical Research Advantage, Inc.
853
mi
from
Phoenix, AZ
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Clinical Research Advantage, Inc.
853
mi
from
Phoenix, AZ
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Good Samaritan Hospital
1169
mi
from
Los Angeles, CA
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Good Samaritan Hospital
1169
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Santa Barbara Cottage Hospital
1242
mi
from
Santa Barbara, CA
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Santa Barbara Cottage Hospital
1242
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Colorado Cardiac Alliance
387
mi
from
Colorado Springs, CO
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Colorado Cardiac Alliance
387
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
JFK Medical Center
1289
mi
from
Atlantis, FL
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
JFK Medical Center
1289
mi
from
Atlantis, FL
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Tallahassee Resesarch Institute, Inc.
924
mi
from
Tallahassee, FL
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Tallahassee Resesarch Institute, Inc.
924
mi
from
Tallahassee, FL
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Provena Saint Joseph Medical Center
577
mi
from
Joliet, IL
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Provena Saint Joseph Medical Center
577
mi
from
Joliet, IL
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
MediSync Clinical Research
mi
from
Cincinnati, OH
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
MediSync Clinical Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Geisinger Wyoming Valley Medical Center
1151
mi
from
Danville, PA
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Geisinger Wyoming Valley Medical Center
1151
mi
from
Danville, PA
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
St. Mary Medical Center
1238
mi
from
Langhorne, PA
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
St. Mary Medical Center
1238
mi
from
Langhorne, PA
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
ARIA Health
mi
from
Philadelphia, PA
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
ARIA Health
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Hospital of the University of Pennsylvania
1223
mi
from
Philadelphia, PA
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Hospital of the University of Pennsylvania
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
The Lankenau Institute for Medical Research
1219
mi
from
Wynnewood, PA
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
The Lankenau Institute for Medical Research
1219
mi
from
Wynnewood, PA
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Wellmont CVA Heart Institute
843
mi
from
Kingsport, TN
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Wellmont CVA Heart Institute
843
mi
from
Kingsport, TN
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Scott & White Memorial Hospital
464
mi
from
Temple, TX
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Scott & White Memorial Hospital
464
mi
from
Temple, TX
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
McKay-Dee Hospital
790
mi
from
Ogden, UT
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
McKay-Dee Hospital
790
mi
from
Ogden, UT
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Sentara Norfolk General Hospital
1181
mi
from
Norfolk, VA
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Sentara Norfolk General Hospital
1181
mi
from
Norfolk, VA
Click here to add this to my saved trials
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated:  4/30/2013
Medical College of Wisconsin
636
mi
from
Milwaukee, WI
CARTO® 3 System and Real Time Intracardiac Ultrasound
CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study
Status: Enrolling
Updated: 4/30/2013
Medical College of Wisconsin
636
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation
Role of Coumadin in Preventing Periprocedural Thrombo-Embolism as a Complication of Radio Frequency Catheter Ablation in High-risk Atrial Fibrillation Patients
Status: Enrolling
Updated:  5/9/2013
St.David's Medical Center
515
mi
from
Austin, TX
Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation
Role of Coumadin in Preventing Periprocedural Thrombo-Embolism as a Complication of Radio Frequency Catheter Ablation in High-risk Atrial Fibrillation Patients
Status: Enrolling
Updated: 5/9/2013
St.David's Medical Center
515
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy of Lean Body Weight-based IV Heparin Dosing in Obese/Morbidly Obese Patients
Assessing Safety and Efficacy of Lean Body Weight-based Intravenous Heparin Dosing in Obese/Morbidly Obese Patients. A Pilot Study
Status: Enrolling
Updated:  5/13/2013
Nazareth Hospital - Mercy Health System
1225
mi
from
Philadelphia, PA
Safety and Efficacy of Lean Body Weight-based IV Heparin Dosing in Obese/Morbidly Obese Patients
Assessing Safety and Efficacy of Lean Body Weight-based Intravenous Heparin Dosing in Obese/Morbidly Obese Patients. A Pilot Study
Status: Enrolling
Updated: 5/13/2013
Nazareth Hospital - Mercy Health System
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation
Status: Enrolling
Updated:  6/4/2013
St.David's Medical Center
515
mi
from
Austin, TX
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation
Status: Enrolling
Updated: 6/4/2013
St.David's Medical Center
515
mi
from
Austin, TX
Click here to add this to my saved trials
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)
Status: Enrolling
Updated:  7/2/2013
Texas Cardiac Arrhythmia Institute, St. David's Medical Center
517
mi
from
Austin, TX
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)
Status: Enrolling
Updated: 7/2/2013
Texas Cardiac Arrhythmia Institute, St. David's Medical Center
517
mi
from
Austin, TX
Click here to add this to my saved trials
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)
Status: Enrolling
Updated:  7/2/2013
Texas Cardiac Arrhythmia Institute, St. David's Hospital
515
mi
from
Austin, TX
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)
Status: Enrolling
Updated: 7/2/2013
Texas Cardiac Arrhythmia Institute, St. David's Hospital
515
mi
from
Austin, TX
Click here to add this to my saved trials
Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes
Use of Oral Steroids Before Circumferential Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation to Improve Outcomes
Status: Enrolling
Updated:  8/13/2013
University of Kansas Medical Center
190
mi
from
Kansas City, KA
Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes
Use of Oral Steroids Before Circumferential Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation to Improve Outcomes
Status: Enrolling
Updated: 8/13/2013
University of Kansas Medical Center
190
mi
from
Kansas City, KA
Click here to add this to my saved trials
Atrial Fibrillation/Flutter Outcome Risk Determination
The "AFFORD" Study: Atrial Fibrillation/Flutter Outcome Risk Determination
Status: Enrolling
Updated:  9/30/2013
Vanderbilt University Medical Center - Emergency Medicine
618
mi
from
Nashville, TN
Atrial Fibrillation/Flutter Outcome Risk Determination
The "AFFORD" Study: Atrial Fibrillation/Flutter Outcome Risk Determination
Status: Enrolling
Updated: 9/30/2013
Vanderbilt University Medical Center - Emergency Medicine
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Status: Enrolling
Updated:  9/30/2013
Central Baptist Hospital
724
mi
from
Lexington, KY
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Status: Enrolling
Updated: 9/30/2013
Central Baptist Hospital
724
mi
from
Lexington, KY
Click here to add this to my saved trials
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Status: Enrolling
Updated:  9/30/2013
Texas Cardiac Arrhythmia Institute
517
mi
from
Austin, TX
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Status: Enrolling
Updated: 9/30/2013
Texas Cardiac Arrhythmia Institute
517
mi
from
Austin, TX
Click here to add this to my saved trials
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Status: Enrolling
Updated:  9/30/2013
Baylor Research Institute
347
mi
from
Dallas, TX
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
Status: Enrolling
Updated: 9/30/2013
Baylor Research Institute
347
mi
from
Dallas, TX
Click here to add this to my saved trials
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
Anticoagulation With Rivaroxaban in Post Cardioversion Patients
Status: Enrolling
Updated:  10/25/2013
Cook County Hosp
608
mi
from
Chicago, IL
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
Anticoagulation With Rivaroxaban in Post Cardioversion Patients
Status: Enrolling
Updated: 10/25/2013
Cook County Hosp
608
mi
from
Chicago, IL
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
683
mi
from
Birmingham, AL
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
853
mi
from
Phoenix, AZ
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
853
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
1318
mi
from
Santa Clara, CA
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
1318
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
1330
mi
from
Bridgeport, CT
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
1330
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
1202
mi
from
Newark, DE
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
1202
mi
from
Newark, DE
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
1128
mi
from
Daytona Beach, FL
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
1128
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
805
mi
from
Decatur, GA
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
805
mi
from
Decatur, GA
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
604
mi
from
Park Ridge, IL
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
604
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
1148
mi
from
Baltimore, MD
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
262
mi
from
Omaha, NE
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
262
mi
from
Omaha, NE
Click here to add this to my saved trials